These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Progress in Elucidating Potential Markers and Mechanisms of Rapid Protection Conferred by the VSV-Vectored Ebola Virus Vaccine. Wong G mBio; 2019 Jul; 10(4):. PubMed ID: 31311887 [TBL] [Abstract][Full Text] [Related]
6. High dose of vesicular stomatitis virus-vectored Ebola virus vaccine causes vesicular disease in swine without horizontal transmission. Morozov I; Monath TP; Meekins DA; Trujillo JD; Sunwoo SY; Urbaniak K; Kim IJ; Narayanan SK; Indran SV; Ma W; Wilson WC; O'Connor C; Dubey S; Troth SP; Coller BA; Nichols R; Martin BK; Feldmann H; Richt JA Emerg Microbes Infect; 2021 Dec; 10(1):651-663. PubMed ID: 33719915 [No Abstract] [Full Text] [Related]
15. Immunization with vesicular stomatitis virus vaccine expressing the Ebola glycoprotein provides sustained long-term protection in rodents. Wong G; Audet J; Fernando L; Fausther-Bovendo H; Alimonti JB; Kobinger GP; Qiu X Vaccine; 2014 Sep; 32(43):5722-9. PubMed ID: 25173474 [TBL] [Abstract][Full Text] [Related]
16. Recent advances in the development of vaccines for Ebola virus disease. Ohimain EI Virus Res; 2016 Jan; 211():174-85. PubMed ID: 26596227 [TBL] [Abstract][Full Text] [Related]
17. Progress towards a vaccine against Ebola to meet emergency medical countermeasure needs. Wolfe DN; Zarrabian AG; Disbrow GL; Espeland EM Vaccine; 2019 Nov; 37(48):7178-7182. PubMed ID: 29199040 [TBL] [Abstract][Full Text] [Related]
18. Clinical development of a recombinant Ebola vaccine in the midst of an unprecedented epidemic. Coller BG; Blue J; Das R; Dubey S; Finelli L; Gupta S; Helmond F; Grant-Klein RJ; Liu K; Simon J; Troth S; VanRheenen S; Waterbury J; Wivel A; Wolf J; Heppner DG; Kemp T; Nichols R; Monath TP Vaccine; 2017 Aug; 35(35 Pt A):4465-4469. PubMed ID: 28647166 [TBL] [Abstract][Full Text] [Related]
19. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs. Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337 [TBL] [Abstract][Full Text] [Related]
20. VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection. Williams KJ; Qiu X; Fernando L; Jones SM; Alimonti JB Viral Immunol; 2015 Feb; 28(1):51-61. PubMed ID: 25494457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]